

## PURPOSE OF BILL: HB 1332

To require the Arkansas Medicaid Program to cover glucagon-like peptide-1 receptor agonists, also known as GLP-1 agonists, when prescribed for weight loss.

## ACTUARIAL STATEMENT

The Fiscal Impact Statement was prepared according to generally accepted actuarial principles and practices, in compliance with ACT 112. The Statement provides an estimate of the financial and actuarial effect of the proposed change(s) on the Plans, if possible. The Statement makes no comment or opinion with regard to the merits of the measure for which the Statement is prepared; however, any identified technical or mechanical defects have been noted.

We have reviewed the input and results of our analysis for reasonableness and relied upon the data and information provided by the Plans and their Claims Processing Contractors.

A handwritten signature in black ink, appearing to read "Patrick Klein".

---

Patrick Klein, FSA, MAAA  
Vice President, Segal

3/31/2025

---

Date

A handwritten signature in black ink, appearing to read "Matthew Kersting".

---

Matthew Kersting, FSA, MAAA  
Vice President, Segal

3/31/2025

---

Date

## PROJECTED COSTS

Plan	Plan Design Change	Estimated Cost/(Savings)
EBD	No Impact	No Impact

## PRICING APPROACH AND COMMENTS

House Bill 1332 requires the Arkansas Medicaid program to cover GLP-1 agonists when prescribed for weight loss. The amendment, dated March 20, 2025, removes coverage requirements for health benefit plans offered, issued, or renewed in Arkansas. Therefore, this bill no longer impacts EBD.